The scope of immunotherapy is widening globally, with therapies being tested and approved for a broader range of cancers and even non-oncology conditions. In India, oncologists are increasingly considering immune checkpoint inhibitors for first-line, second-line, and combination regimens — fuelling steady India Keytruda Market Growth as treatment protocols evolve and demand increases for advanced drug combinations.

Combination protocols — pairing immunotherapy with chemotherapy, targeted therapy, or radiotherapy — are becoming more common in oncology centers that can support complex care pathways. Such regimens often require close monitoring, specialized infusion infrastructure, and multidisciplinary care teams — all signifying higher-value treatment and expanding revenue potential for healthcare providers and suppliers alike.

Moreover, compassionate-use programs and expanded access initiatives are helping patients with limited options receive immunotherapy, contributing to market volume even before full insurance reimbursement coverage becomes widespread. As these pathways become more structured, long-term growth becomes more predictable and sustainable.

FAQs
Q1. Why do combination therapies increase demand for immunotherapy drugs?
Because they expand treatment candidacy, extend therapy duration, and often improve clinical outcomes — increasing overall drug utilization.
Q2. How do access and compassionate-use programs impact market growth?
They allow broader patient reach even in under-served regions and support therapy adoption ahead of full reimbursement coverage.

get more insights @ 
https://www.marketresearchfuture.com/reports/india-keytruda-market-45328